Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin.

Antimicrobial Agents and Chemotherapy
W R BowieP J Jewesson

Abstract

New fluoroquinolones have generally been well tolerated. In a double-blind evaluation of oral fleroxacin, using 400, 600, or 800 mg once daily for 7 days in an ambulatory setting for treatment of uncomplicated genital infections, we encountered unexpectedly high rates of adverse reactions. The objective of this analysis was to determine whether any factors in addition to dose could be found to account for our observations. Adverse reactions developed in 66 (84%) of 79 individuals, and severe reactions arose in 38 (48%). Most frequent were central nervous system reactions (70%), with insomnia being especially frequent (49%); gastrointestinal reactions (39%) and photosensitivity reactions (10%) were also common. Development of any reaction (central nervous system reactions, insomnia, and severe intestinal reactions) was dose related. Development of photosensitivity reactions correlated with an outdoor occupation. No other factors, including usual daily caffeine use, correlated with the development of adverse reactions. In our study, fleroxacin taken as a single daily 600- or 800-mg dose was associated with an unacceptably high rate of adverse reactions. Other studies are required to determine whether this problem is unique to fle...Continue Reading

References

Oct 1, 1989·Antimicrobial Agents and Chemotherapy·W R BowieD W Megran
Nov 1, 1985·Antimicrobial Agents and Chemotherapy·D C Hooper, J S Wolfson
Apr 1, 1986·European Journal of Clinical Microbiology·G ArcieriB O'Brien
Sep 1, 1988·The Journal of Antimicrobial Chemotherapy·G Jüngst, R Mohr
Sep 1, 1988·The Journal of Antimicrobial Chemotherapy·P G Davey
Oct 1, 1988·The Journal of Antimicrobial Chemotherapy·E WeidekammD Dell
Oct 1, 1988·The Journal of Antimicrobial Chemotherapy·F SorgelP Muth
Oct 1, 1988·The Journal of Antimicrobial Chemotherapy·F SörgelP Muth
Oct 1, 1988·The Journal of Antimicrobial Chemotherapy·D J GriggsJ P Ashby
Oct 1, 1988·The Journal of Antimicrobial Chemotherapy·P M ShahH Knothe
Oct 1, 1988·The Journal of Antimicrobial Chemotherapy·R A PustH Meier-Ewert
Jan 1, 1988·Reviews of Infectious Diseases·H Halkin
Nov 1, 1986·The Journal of Antimicrobial Chemotherapy·P Ball
Oct 1, 1986·Antimicrobial Agents and Chemotherapy·W R BowieL Sibau
Nov 1, 1981·Antimicrobial Agents and Chemotherapy·H H HandsfieldK K Holmes
Jan 1, 1982·The Medical Clinics of North America·A R Mayrer, V T Andriole

❮ Previous
Next ❯

Citations

Sep 29, 2001·Pharmazie in unserer Zeit·R Stahlmann, K Riecke
May 1, 1993·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·I M HoepelmanJ Verhoef
Jul 1, 1993·International Journal of Antimicrobial Agents·E Ludwig
Jun 8, 2002·Toxicology Letters·Ralf Stahlmann
Feb 1, 1997·Journal of Photochemistry and Photobiology. B, Biology·G KlecakH Urwyler
May 1, 1995·Journal of Toxicology and Environmental Health·S TakayamaH Shimada
Jun 9, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robert C Owens, Paul G Ambrose
Apr 5, 2000·The Journal of Antimicrobial Chemotherapy·J FergusonS A Willavize
Jun 1, 1993·International Journal of Dermatology·R T ScheifeE L Decker
Feb 17, 1999·Photodermatology, Photoimmunology & Photomedicine·I ManJ Ferguson
Nov 1, 1996·Photochemistry and Photobiology·Y TokuraM Takigawa
Oct 1, 1989·Antimicrobial Agents and Chemotherapy·W R BowieD W Megran
Jun 1, 1990·Antimicrobial Agents and Chemotherapy·M ParentM LeBel
Oct 21, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jacques SchrenzelUNKNOWN Swiss Staphylococcal Study Group
Aug 12, 2014·Journal of Photochemistry and Photobiology. B, Biology·Paola PeruccaLucia Anna Stivala
Feb 7, 1991·The New England Journal of Medicine·D C Hooper, J S Wolfson
Dec 30, 1991·The American Journal of Medicine·J S Wolfson, D C Hooper
Mar 24, 2015·Tuberculosis·S TheeH S Schaaf
Mar 12, 2005·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·F Van BambekeP M Tulkens
Apr 20, 2000·The Annals of Pharmacotherapy·L E BoccuminiK H Kaidbey
Feb 11, 1999·The Annals of Pharmacotherapy·D F Thompson, D R Pierce
Dec 30, 1991·The American Journal of Medicine·L C Parish, J A Witkowski
Jan 30, 2007·Chemotherapy·Hiroki YamaguchiJingoro Shimada
Feb 27, 1993·BMJ : British Medical Journal·E T SmythA E Tattersfield
Jan 22, 2003·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Roberto LeoneAnita Conforti
Mar 19, 2003·Drugs & Aging·Ralf Stahlmann, Hartmut Lode
Jan 13, 2001·The Medical Clinics of North America·R C Owens, P G Ambrose

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.